Top

Published in:

01-09-2022 | Darolutamide | Clinical study

Darolutamide AE costs lower versus apalutamide or enzalutamide

Published in: Reactions Weekly | Issue 1/2022

Excerpt

In patients with non-metastatic castration-resistant prostate cancer (nmCRPC), costs of adverse events (ARs) requiring hospitalisation are lower with darolutamide than with apalutamide or enzalutamide, according to findings of a Bayer-funded study published in Advances in Therapy. …

Shore N, et al. The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison Advances in Therapy : 26 Aug 2022. Available from: URL: http://doi.org/10.1007/s12325-022-02245-8

Title: Darolutamide AE costs lower versus apalutamide or enzalutamide
Publication date: 01-09-2022
Publisher: Springer International Publishing
Keywords: Darolutamide
Apalutamide
Enzalutamide
Androgens
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-22870-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Darolutamide AE costs lower versus apalutamide or enzalutamide

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Multiple drugs

Nitric-oxide

Lenalidomide

Etomidate

Ledipasvir/sofosbuvir

Levamisole